News
Here's the main clause: You can do whatever you like with that $30,000 and, as long as you don't blow it on the slots or take a risk on a couple of stocks, you'll probably be OK. That sweeping ...
When back-tested to 1871, this forecasting tool has an immaculate track record of projecting where stocks will head next.
Recognify Life Sciences, a company Atai Life Sciences is a strategic investor in, said its trial for a cognitive decline treatment missed its primary endpoint. Atai shares fell 13% to $3.08 in ...
Italian oil major Eni raised some 2025 growth projections and said it would buy back up to roughly $1.76 billion of shares over the year despite commodity and currency headwinds. Write to Rob Curran ...
Find insight on EFG International, Deutsche Bank and more in the latest Market Talks covering Financial Services.
Investors are benefiting as the FTSE 100 hits record highs - here are the best performing shares and funds so far this year ...
Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.
DIAX writes options on a portfolio of constituents of the Dow Jones index and makes it possible to collect a higher yield than average. See why the Fund is a Buy.
Northrop Grumman is positioned to capitalize on international demand, in the Middle East and Europe, fueled by regional ...
Find insight on GM, Stellantis and more in the latest Market Talks covering Auto and Transport.
Find insight on Akzo Nobel, Steel Dynamics, Givaudan and more in the latest Market Talks covering Basic Materials.
Verizon's post-earnings gain made it the best Dow Jones stock today. All in all, the blue chip Dow Jones Industrial Average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results